<?xml version="1.0" encoding="UTF-8"?>
<p id="Par11">Enrolled patients were those with aggressive de novo or transformed NHL, who had relapsed or were refractory to at least two previous multi-agent chemotherapy regimens, with previous therapy including at least one standard anthracycline-based regimen with a response of at least 24 weeks. During the course of the study, the protocol was amended to exclude patients with no previous treatment with rituximab in countries where it was commercially available [
 <xref ref-type="bibr" rid="CR15">15</xref>, 
 <xref ref-type="bibr" rid="CR16">16</xref>]. Patients also had to have a European Cooperative Oncology Group performance status of 0–2, measurable disease, a left ventricular ejection fraction of at least 50%, adequate bone marrow and organ function and no persisting toxicities from previous lines of treatment. Patients were excluded if they had received a cumulative dose of doxorubicin or equivalent exceeding 450 mg/m
 <sup>2</sup>, or if they had New York Heart Association grade 3 or 4 cardiovascular abnormalities [
 <xref ref-type="bibr" rid="CR15">15</xref>].
</p>
